2022
Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study.
Iseke S, Zeevi T, Kucukkaya AS, Raju R, Gross M, Haider SP, Petukhova-Greenstein A, Kuhn TN, Lin M, Nowak M, Cooper K, Thomas E, Weber MA, Madoff DC, Staib L, Batra R, Chapiro J. Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study. American Journal Of Roentgenology 2022, 220: 245-255. PMID: 35975886, PMCID: PMC10015590, DOI: 10.2214/ajr.22.28077.Peer-Reviewed Original ResearchConceptsEarly-stage hepatocellular carcinomaLiver transplantHepatocellular carcinomaImaging featuresPosttreatment recurrenceOrgan allocationMean AUCLiver transplant eligibilityPretreatment clinical characteristicsPretreatment MRI examinationsKaplan-Meier analysisKaplan-Meier curvesClinical characteristicsImaging surveillanceTherapy allocationTransplant eligibilityUnderwent treatmentClinical parametersRetrospective studyUnpredictable complicationMRI dataConcept studyPoor survivalClinical impactPretreatment MRI
2021
Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient group
2020
Is There a Role for Combination, Single-Session Selective Transarterial Embolization and Microwave Ablation for Large Renal Masses?
LaRussa S, Vanden Berg RW, Craig KM, Madoff DC, McClure TD. Is There a Role for Combination, Single-Session Selective Transarterial Embolization and Microwave Ablation for Large Renal Masses? CardioVascular And Interventional Radiology 2020, 43: 1468-1473. PMID: 32613266, DOI: 10.1007/s00270-020-02568-5.Peer-Reviewed Original ResearchConceptsLarge renal massTransarterial embolizationRenal tumorsRenal massesMicrowave ablationCharleston Comorbidity IndexLarge renal tumorsEvidence of recurrencePost-procedure complicationsAverage tumor sizeSelective transarterial embolizationSmall renal tumorsClear cell carcinomaMeeting inclusion criteriaPatient demographic informationGroin hematomaComorbidity indexResultsEleven patientsAverage BMICase seriesSuccessful ablationTumor sizeCell carcinomaMean ageRENAL scoreQuality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis
Kahn S, Julian J, Kearon C, Gu C, Cohen D, Magnuson E, Comerota A, Goldhaber S, Jaff M, Razavi M, Kindzelski A, Schneider J, Kim P, Chaer R, Sista A, McLafferty R, Kaufman J, Wible B, Blinder M, Vedantham S, Sichlau M, Vlahos A, Smith S, Thalheimer Q, Singh N, Harting R, Gocke J, Guth S, Shah N, Brady P, Schatz M, Horrow M, Markazi P, Forouzan L, Matalon T, Hertzog D, Goday S, Kennedy M, Kaplan R, Campbell T, Hartman J, Nahum E, Venkat A, Krishnamurthy V, Rectenwald J, Henke P, Eliason J, Willatt J, Escobar G, Samuels S, Katzen B, Benenati J, Powell A, Pena C, Wallach H, Gandhi R, Schneider J, Kim S, Hashemi F, Boyle J, Patel N, Verta M, Leung D, Garcia M, Blatt P, Khatri J, Epstein D, Ryan R, Sweeny T, Stillabower M, Kimbiris G, Raman T, Sierzenski P, Getto L, Dignazio M, Sierzenski P, Horvath M, Gornik H, Bartholomew J, Shishehbor M, Peacock F, Joseph D, Kim S, Mahlay N, Clair D, Lyden S, Kapoor B, McLennon G, Pierce G, Newman J, Spain J, Gill A, Hamilton A, Rizzo A, Park W, Dietzek A, Galin I, Plummer D, Hsu R, Broderick P, Keller A, Sayeed S, Slater D, Lustberg H, Akus J, Sidman R, Dhami M, Kohanski P, Bulgaru A, Dulala R, Burch J, Kapur D, Yang J, Ranson M, Wladis A, Varnagy D, Mekhail T, Winter R, Perez-Izquierdo M, Motew S, Royd-Kranis R, Workman R, Kribbs S, Hogsette G, Moore P, Thomason B, Means W, Bonsall R, Stewart J, Golwya D, Azene E, Bottner W, Bishop W, Clayton D, Gundersen L, Riherd J, Shakhnovich I, Ziegelbein K, Chang T, Sharma K, Allison S, Banovac F, Cohen E, Furlong B, Kessler C, McCullough M, Spies J, Lin J, Kaatz S, Getzen T, Miller J, Schwartz S, Kabbani L, McVinnie D, Rundback J, Manno J, Schwab R, Cole R, Herman K, Singh D, Barkama R, Patel A, Comerota A, Pigott J, Seiwert A, Whalen R, Russell T, Assi Z, Kazanjian S, Yobbagy J, Kaminski B, Kaufman A, Begeman G, DiSalle R, Thakur S, Kim P, Jacquet M, Dykes T, Gerding J, Baker C, Debiasto M, Mittleider D, Higgins G, Amberson S, Pezzuti R, Gallagher T, Schainfeld R, Wicky S, Kalva S, Walker G, Salazar G, Pomerantz B, Patel V, Kabrhel C, Iqbal S, Gangull S, Oklu R, Brannan S, Misra S, Bjarnason H, Ashrani A, Caccavale M, Fleming C, Friese J, Heit J, Kalra M, Macedo T, McBane R, McKusick M, Stockland A, Woodrum D, Wysokinski W, Verma A, Davis A, Chung J, Nicker D, Anderson B, Stein R, Weiss M, Patel P, Rilling W, Tutton S, Hieb R, Hohenwalter E, Colella M, Gosset J, White S, Lewis B, Brown K, Rossi P, Seabrook G, Guimaraes M, Selby J, McGary W, Hannegan C, Robison J, Brothers T, Elliott B, Garg N, Anderson M, Uflacker R, Schonholz C, Raney L, Greenberg C, Kaufman J, Keller F, Kolbeck K, Landry G, Mitchell E, Barton R, DeLoughery T, Kalbfleisch N, Minjarez R, Lakin P, Liem T, Moneta G, Farsad K, Fleischman R, French L, Marques V, Al−Hassani Y, Sawar A, Taylor F, Patel R, Malhotra R, Kim D, Hashemi F, Boyle J, Patel R, Padnick M, Gurley M, Cucher F, Sterrenberg R, Deepthi G, Cumaranatunge G, Bhatla S, Jacobs D, Dolen E, Gamboa P, Dean L, Davis T, Lippert J, Khanna S, Schirf B, Silber J, Wood D, McGraw J, LaPerna L, Willette P, Murphy T, Cerezo J, Dhangana R, Ahn S, Dubel G, Haas R, Jay B, Prince E, Soares G, Klinger J, Lambiase R, Jay G, Tubbs R, Beland M, Hampson C, O'Hara R, Thompson C, Beland M, Frodsham A, Gardiner F, Jaffan A, Keating L, Zafar A, Alicic R, Raabe R, Brower J, McClellan D, Pellow T, Zylak C, Davis J, Reilly M, Symington K, Seibold C, Nachreiner R, Murray D, Murray S, Saha S, Luna G, Hodgson K, McLafferty R, Hood D, Moore C, Griffen D, Hurst D, Lubbers D, Kim K, Warren B, Engel J, Suresh D, VanderWoude E, Razdan R, Hutchins M, Rounsborg T, Midathada M, Moravec D, Tilford J, Kim D, Beckman J, Razavi M, Openshaw K, Flanigan D, Loh C, Dorne H, Chan M, Thomas J, Psaila J, Ringold M, Fisher J, Lipcomb A, Oskin T, Wible B, Coleman B, Elliott D, Gaddis G, Cochran C, Natarajan K, Bick S, Cooke J, Hedderman A, Greist A, Miller L, Martinez B, Flanders V, Underhill M, Hofmann L, Sze D, Kuo W, Louie J, Hwang G, Hovsepian D, Kothary N, Berube C, Schreiber D, Jeffrey B, Schor J, Deitch J, Singh K, Hahn B, Ardolic B, Gupta S, Bashir R, Rao A, Garg M, Patil P, Zack C, Cohen G, Schmieder F, Lakhter V, Sacks D, Guay R, Scott M, Cunningham K, Sigal A, Cescon T, Leasure N, Dhurairaj T, Muck P, Knochel K, Lohr J, Barreau J, Recht M, Bhaskaran J, Brahmamdam R, Draper D, Mehta A, Maher J, Sharafuddin M, Lentz S, Nugent A, Sharp W, Kresowik T, Nicholson R, Sun S, Youness F, Pascarella L, Ray C, Knuttinen M, Bui J, Gaba R, Dobiesz V, Shamim E, Nimmagadda S, Peace D, Zain A, Palumto A, Haskal Z, Hirshon J, Richard H, Verceles A, Wong-You-Chong J, Othee B, Patel R, Iliescu B, Williams D, Gemmete J, Krishnamurthy V, Cwikiel W, Cho K, Schields J, Vellody R, Novelli P, Dasika N, Wakefield T, Rectenwald J, Henke P, Desmond J, Froehlich J, Khaja M, Hunter D, Golzarian J, Cressman E, Dotta Y, Schmiechen N, Marek J, Garcia D, Tawil I, Langsfeld M, Moll S, Mauro M, Stavas J, Burke C, Dixon R, Yu H, Keagy B, Kim K, Kasthuri R, Key N, Chaer R, Makaroun M, Rhee R, Cho J, Baril D, Marone L, Hseih M, Feterik K, Smith R, Jeyabalan G, Rogers J, Vinik R, Kinikini D, Kraiss L, Mueller M, Pendleton R, Rondina M, Sarfati M, Wanner N, Johnson S, Hopkins C, Ihnat D, Angle J, Matsumoto A, Harthun N, Turba U, Saad W, Uthlaut B, Nannapaneni S, Ling D, Sabri S, Kern J, Macik B, Hoke G, Park A, Stone J, Sneed B, Syverud S, Davidson K, Sharma A, Haskal Z, Wilkins L, Black C, Asay M, Hatch D, Smilanich R, Patten C, Brown S, Nielsen R, Alward W, Collins J, Nokes M, Geary R, Edwards M, Godshall C, Levy P, Winokur R, Sista A, Madoff D, Lee K, Pua B, DeSancho M, Milizia R, Gao J, Goday S, Kennedy M, Kaplan R, Campbell T, McLean G, Hartman J, Nahum E, Khalid S, Vedantham S, Lewis L, Saad N, Thoelke M, Pallow R, Klein S, Sicard G, Cohen D, Comerota A, Gornik H, Jaff M, Julian J, Kahn S, Kearon C, Kee S, Kindzelski A, Lewis L, Magnuson E, Razavi M, Murphy T, Vedantham S. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2020, 8: 8-23.e18. PMID: 31843251, PMCID: PMC7681916, DOI: 10.1016/j.jvsv.2019.03.023.Peer-Reviewed Original ResearchConceptsPharmacomechanical catheter-directed thrombolysisProximal deep venous thrombosisDeep venous thrombosisQuality of lifeDisease-specific QOLIliofemoral deep venous thrombosisCatheter-directed thrombolysisPhysical component summaryVenous thrombosisPCDT groupChange scoresDVT patientsQOL measuresForm Health Survey Physical Component SummaryExtent of DVTLong-term QOLAssessor-blinded randomized trialGeneral QOL measuresVenous Insufficiency EpidemiologicalAcute venous thrombosisDisease-specific QOL measuresGreater improvementThrombolysis trialsCommon femoralComponent summary
2019
Use of Virtual Injection Software to Aid in Microcatheter Positioning during Transarterial Chemoembolization
Soliman MM, Stein SI, Doustaly R, Madoff DC. Use of Virtual Injection Software to Aid in Microcatheter Positioning during Transarterial Chemoembolization. Journal Of Vascular And Interventional Radiology 2019, 30: 1646-1648. PMID: 31471197, DOI: 10.1016/j.jvir.2019.07.003.Peer-Reviewed Original ResearchConceptsSoftwareManagement of Advanced Stage Hepatocellular Carcinoma with Extensive Portal Vein Tumor Thrombus Using an Adjustable Dual Balloon Occlusion Technique
Madoff DC, Kim D, Holzwanger DJ, Kishore SA, Friedman T. Management of Advanced Stage Hepatocellular Carcinoma with Extensive Portal Vein Tumor Thrombus Using an Adjustable Dual Balloon Occlusion Technique. Journal Of Vascular And Interventional Radiology 2019, 30: 1145-1147. PMID: 31133450, DOI: 10.1016/j.jvir.2019.01.006.Peer-Reviewed Original Research
2017
Multicenter Trial of the VenaTech Convertible Vena Cava Filter
Hohenwalter EJ, Stone JR, O’Moore P, Smith SJ, Selby JB, Lewandowski RJ, Samuels S, Kiproff PM, Trost DW, Madoff DC, Handel J, Gandras EJ, Vlahos A, Rilling WS. Multicenter Trial of the VenaTech Convertible Vena Cava Filter. Journal Of Vascular And Interventional Radiology 2017, 28: 1353-1362. PMID: 28821379, DOI: 10.1016/j.jvir.2017.06.032.Peer-Reviewed Original ResearchConceptsVena cava filtersCava filtersDevice-related adverse eventsHigh-risk traumaAdverse event ratesSingle-arm studyFailure of anticoagulationTechnical success rateLong-term safetyConverted patientsAdverse eventsPulmonary embolismSurgical prophylaxisVenous thromboembolismMulticenter trialCaval filtersRight atriumSurgical removalClinical assessmentProcedure timePatientsEvent ratesMean timeSuccess rateMonths
2014
Characterization of In Vivo Ablation Zones Following Percutaneous Microwave Ablation of the Liver with Two Commercially Available Devices: Are Manufacturer Published Reference Values Useful?
Winokur RS, Du JY, Pua BB, Talenfeld AD, Sista AK, Schiffman MA, Trost DW, Madoff DC. Characterization of In Vivo Ablation Zones Following Percutaneous Microwave Ablation of the Liver with Two Commercially Available Devices: Are Manufacturer Published Reference Values Useful? Journal Of Vascular And Interventional Radiology 2014, 25: 1939-1946.e1. PMID: 25307296, DOI: 10.1016/j.jvir.2014.08.014.Peer-Reviewed Original ResearchBland embolization versus chemoembolization of hepatocellular carcinoma before transplantation
Kluger MD, Halazun KJ, Barroso RT, Fox AN, Olsen SK, Madoff DC, Siegel AB, Weintraub JL, Sussman J, Brown RS, Cherqui D, Emond JC. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transplantation 2014, 20: 536-543. PMID: 24493271, PMCID: PMC4095977, DOI: 10.1002/lt.23846.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, HepatocellularCase-Control StudiesChemoembolization, TherapeuticDisease-Free SurvivalEnd Stage Liver DiseaseFemaleHumansKaplan-Meier EstimateLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTime FactorsTreatment OutcomeConceptsWait-list dropoutTAE patientsTACE patientsTransarterial embolizationTransarterial chemoembolizationHCC patientsEnd-stage liver disease (MELD) scoreSurvival rateRecurrence-free survival ratesMethods of embolizationRadiographic tumor sizeLiver Disease scoreOverall survival rateRecurrence-free survivalKaplan-Meier survivalBland transarterial embolizationCase-control studySignificant demographic differencesExplant tumorsPrimary endpointTreat basisTumor sizeHepatocellular carcinomaDisease scorePatients
2011
Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle Albumin-Bound PaclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-Bound PaclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albuminHigh Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome
Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome. Journal Of Clinical Oncology 2011, 29: 1083-1090. PMID: 21263087, PMCID: PMC3068054, DOI: 10.1200/jco.2010.32.6132.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChemotherapy, AdjuvantColorectal NeoplasmsFemaleHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyPatient SelectionRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTexasTime FactorsTomography, X-Ray ComputedTreatment OutcomeConceptsAdvanced colorectal liver metastasesTwo-stage resectionColorectal liver metastasesLiver metastasesComplete resectionSurvival rateMedical groupMajor postoperative complicationsSurvival of patientsChemotherapy initiationNonsurgical patientsOnly chemotherapyPostoperative complicationsColorectal metastasesMetastatic diseaseObjective responseWorse survivalTreat analysisGood respondersExcellent outcomesTSR groupInclusion criteriaResectionPatientsChemotherapy
2010
Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma
Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY. Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma. Cancer Investigation 2010, 29: 49-55. PMID: 21166498, DOI: 10.3109/07357907.2010.535052.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationOverall survivalCutaneous melanoma metastaticExtrahepatic metastatic sitesHepatic arterial chemoembolizationMedian overall survivalLactate dehydrogenase levelsType of treatmentMelanoma metastaticRadiologic responseDisease stabilizationLiver metastasesMost patientsPatient ageArterial chemoembolizationPrognostic factorsLiver diseaseMetastatic sitesCutaneous melanomaMedical recordsDehydrogenase levelsPatientsSignificant predictorsChemoembolizationSurvivalExploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases
Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases. Clinical Colorectal Cancer 2010, 9: 311-314. PMID: 21208846, PMCID: PMC3088086, DOI: 10.3816/ccc.2010.n.045.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsDrug Resistance, NeoplasmFemaleFluorouracilHepatic ArteryHumansInfusions, Intra-ArterialLeucovorinLiver NeoplasmsMaleMiddle AgedOrganoplatinum CompoundsOvarian NeoplasmsOxaliplatinPilot ProjectsSalvage TherapySurvival RateTomography, X-Ray ComputedTreatment OutcomeConceptsExtensive liver metastasesRefractory solid tumorsLiver metastasesTotal bilirubinSolid tumorsBaseline serum total bilirubinHepatic arterial infusion (HAI) oxaliplatinMedian Child-Pugh scoreAdvanced refractory malignanciesGrade 1 fatigueMedian total bilirubinRegional hepatic therapySystemic anticancer agentsChild-Pugh scoreCommon side effectsSerum total bilirubinPilot clinical trialElevated bilirubinLiver involvementPartial responseHepatic insufficiencyMedian ageRefractory malignanciesClinical trialsDisease progressionHepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver
Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P. Hepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver. American Journal Of Clinical Oncology 2010, 33: 474-480. PMID: 19935383, DOI: 10.1097/coc.0b013e3181b4b065.Peer-Reviewed Original ResearchConceptsHepatic arterial chemoembolizationOcular melanoma metastaticProgression-free survival durationMedian OS durationOverall survivalLactate dehydrogenase levelsMelanoma metastaticRadiologic responseLiver involvementSurvival durationOS durationDehydrogenase levelsResponse rateBaseline lactate dehydrogenase levelsHigher lactate dehydrogenase levelsMedian overall survivalTumor response rateHepatic artery chemoembolizationShorter overall survivalStable diseaseDisease stabilizationProgressive diseaseArterial chemoembolizationMost patientsPartial response
2009
Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors
Kobayashi K, Szklaruk J, Trent JC, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, Hicks ME, Gupta S. Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors. American Journal Of Clinical Oncology 2009, 32: 574-581. PMID: 19636238, DOI: 10.1097/coc.0b013e31819cca35.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesDrug Resistance, NeoplasmEmbolization, TherapeuticFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHepatic ArteryHumansImatinib MesylateLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPiperazinesPrognosisProtein-Tyrosine KinasesPyrimidinesRetrospective StudiesSurvival RateTreatment OutcomeConceptsImatinib-resistant gastrointestinal stromal tumorsGastrointestinal stromal tumorsProgressive liver metastasesHepatic arterial embolizationResponse Evaluation CriteriaOverall survival rateStromal tumorsArterial embolizationLiver metastasesSurvival rateRadiologic responseStable diseaseExtrahepatic metastasesPartial responseSurvival timeMedian progression-free survival timeSolid tumorsProgression-free survival ratesMedian overall survival timeProgression-free survival timeResponse criteriaCox proportional hazards modelAppreciable survival benefitEfficacy of embolotherapyProgression-free survivalMultiple hepatic artery aneurysms in a patient with systemic lupus erythematosus
Pollono E, Madoff D, Spence S, Suarez-Almazor M. Multiple hepatic artery aneurysms in a patient with systemic lupus erythematosus. Lupus 2009, 19: 93-95. PMID: 19884215, DOI: 10.1177/0961203309345721.Peer-Reviewed Original ResearchMeSH KeywordsAneurysmEmbolization, TherapeuticFemaleHepatic ArteryHumansLupus Erythematosus, SystemicMiddle AgedConceptsSystemic lupus erythematosusLupus erythematosusGI tractMultiple hepatic artery aneurysmsComplications of patientsHepatic artery aneurysmLower GI tractEvidence of lesionsHepatic aneurysmSubsequent abscessGastrointestinal bleedingGI bleedingSystemic vasculitisPercutaneous drainageArterial aneurysmsArtery aneurysmHepatic arteryEndovascular embolizationMultiple aneurysmsStandard endoscopyApparent causePatientsAneurysmsBleedingFurther complicationsThree Hundred and One Consecutive Extended Right Hepatectomies
Kishi Y, Abdalla EK, Chun YS, Zorzi D, Madoff DC, Wallace MJ, Curley SA, Vauthey JN. Three Hundred and One Consecutive Extended Right Hepatectomies. Annals Of Surgery 2009, 127: 171-179. PMID: 19730239, DOI: 10.1097/sla.0b013e3181b674df.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBilirubinChildChi-Square DistributionEmbolization, TherapeuticEndpoint DeterminationFemaleHepatectomyHumansLiverLiver Function TestsLogistic ModelsMaleMiddle AgedOutcome and Process Assessment, Health CarePatient SelectionPortal VeinPostoperative ComplicationsPreoperative CareRetrospective StudiesRisk FactorsStatistics, NonparametricConceptsPreoperative portal vein embolizationPostoperative liver insufficiencySafe hepatic resectionPreoperative PVEExtended right hepatectomyLiver insufficiencyRight hepatectomyHepatic resectionPostoperative outcomesEnd pointLiver volumetryIntraoperative blood transfusionPrimary end pointSecondary end pointsLiver volume ratioPortal vein embolizationShort-term outcomesBody mass indexTotal liver volumeMultivariate logistic regressionFLR volumeFuture liverVein embolizationBlood transfusionConsecutive patientsMajor hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival
Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO, Curley SA, Abdalla EK, Vauthey JN. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009, 145: 399-405. PMID: 19303988, DOI: 10.1016/j.surg.2008.10.009.Peer-Reviewed Original ResearchConceptsPreoperative portal vein embolizationMajor hepatic resectionPreoperative PVEPVE groupHepatic resectionPortal vein embolizationHepatocellular carcinomaPerioperative outcomesDFS ratesPerioperative deathsVein embolizationSurvival rateDisease-free survival ratesPreoperative transarterial chemoembolizationOverall postoperative complicationsRemnant liver volumeImproved perioperative outcomesOverall survival rateAmerican Joint CommitteeHepatitis B virusHepatitis C virusPerioperative mortalityPerioperative riskPostoperative complicationsOverall survival
2008
Is embolization of segment 4 portal veins before extended right hepatectomy justified?
Kishi Y, Madoff DC, Abdalla EK, Palavecino M, Ribero D, Chun YS, Vauthey JN. Is embolization of segment 4 portal veins before extended right hepatectomy justified? Surgery 2008, 144: 744-751. PMID: 19081016, PMCID: PMC5901738, DOI: 10.1016/j.surg.2008.05.015.Peer-Reviewed Original ResearchConceptsPreoperative portal vein embolizationPortal vein embolizationPortal veinHypertrophy rateVein embolizationRight portal vein embolizationExtended right hepatectomyLiver remnant volumeMajor hepatectomyRight hepatectomyCurative hepatectomySubsequent resectionClinical outcomesRemnant volumeEmbolizationComplicationsPatientsAbsolute increaseHepatectomyUninjured liverSignificant differencesVeinSegment 2Volume gainResectionChemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases
Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases. Annals Of Surgical Oncology 2008, 15: 2765. PMID: 18636296, PMCID: PMC5901734, DOI: 10.1245/s10434-008-0035-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsEmbolization, TherapeuticFemaleFollow-Up StudiesHumansLiver NeoplasmsLiver RegenerationMaleMiddle AgedOrganoplatinum CompoundsOxaliplatinPortal VeinPrognosisProspective StudiesSurvival RateTreatment OutcomeConceptsPortal vein embolizationColorectal liver metastasesVascular endothelial growth factorLiver metastasesLiver regenerationPreoperative chemotherapyFLR hypertrophyLiver resectionVein embolizationFuture liver remnant volumeFLR volume increaseMajor liver resectionLiver remnant volumeEffect of chemotherapyImpairs liver regenerationEndothelial growth factorConclusionPreoperative chemotherapyConcurrent bevacizumabProspective databaseRight hepatectomyPostoperative outcomesConsecutive patientsRemnant volumeBevacizumabMurine model